Sage Therapeutics (SAGE) Earns “Outperform” Rating from BMO Capital Markets
BMO Capital Markets reissued their outperform rating on shares of Sage Therapeutics (NASDAQ:SAGE) in a research report released on Thursday morning, The Fly reports. BMO Capital Markets currently has a $203.00 price objective on the biopharmaceutical company’s stock.
SAGE has been the topic of several other reports. Stifel Nicolaus reaffirmed a buy rating and set a $91.00 price objective (down from $104.00) on shares of Sage Therapeutics in a report on Wednesday, September 13th. J P Morgan Chase & Co reaffirmed a buy rating on shares of Sage Therapeutics in a report on Thursday, August 31st. Needham & Company LLC increased their price objective on shares of Sage Therapeutics from $86.00 to $100.00 and gave the company a buy rating in a report on Friday, November 10th. Goldman Sachs Group reaffirmed a buy rating and set a $87.00 price objective on shares of Sage Therapeutics in a report on Friday, October 6th. Finally, Chardan Capital raised shares of Sage Therapeutics from a neutral rating to a buy rating and increased their price objective for the company from $60.00 to $140.00 in a report on Friday, November 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $171.21.
Sage Therapeutics (SAGE) traded up $11.07 on Thursday, reaching $167.34. Sage Therapeutics has a 1-year low of $44.55 and a 1-year high of $173.36.
Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.98) by $0.01. The business’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts expect that Sage Therapeutics will post -7.4 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Sage Therapeutics by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 138 shares during the last quarter. Hershey Trust Co. acquired a new stake in shares of Sage Therapeutics in the third quarter valued at about $118,000. Oppenheimer Asset Management Inc. raised its position in shares of Sage Therapeutics by 412.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 1,565 shares during the last quarter. Turner Investments LLC acquired a new stake in shares of Sage Therapeutics in the second quarter valued at about $159,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Sage Therapeutics in the second quarter valued at about $175,000. Institutional investors and hedge funds own 95.40% of the company’s stock.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.